Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)

Vertex Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Short-term Investments rose 14.89% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 14.89% YoY), while the FY2025 annual figure was $1.5 billion, down 1.49% from the prior year.
• Short-term Investments was $1.8 billion for Q1 2026 at Vertex Pharmaceuticals, up from $1.5 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $1.8 billion in Q1 2026 to a low of $274.5 million in Q4 2022.
• Historically, Short-term Investments has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments plunged 62.39% in 2022, then soared 209.36% in 2023.
• A 5-year view of Short-term Investments shows it stood at $274.5 million in 2022, then jumped by 209.36% to $849.2 million in 2023, then surged by 82.09% to $1.5 billion in 2024, then decreased by 1.49% to $1.5 billion in 2025, then advanced by 15.13% to $1.8 billion in 2026.
• The last three Short-term Investments figures came in at $1.8 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.